Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA GENERIC DIVISION's 180 DAY ANDA REVIEW TIME LIMIT COULD EXPEDITE Rx-TO-OTC SWITCHES, FDA's SEIFE TELLS P-A SCIENTIFIC CONFERENCE; TWO-STEP PROCESS OUTLINED

Executive Summary

The FDA Generic Drug Division's 180-day statutory limit for the review of ANDA petitions could be used to expedite the approval of Rx-to-OTC switches, FDA Generic Drug Division Director Marvin Seife, MD, told the Proprietary Association's Research & Scientific Development Conference in Philadelphia. In a Nov. 12 "regulatory roundtable" session, Seife nd Generic Division Review Support Branch Chief David Rosen expressed a willingness to help expedite switches by moving applications under the auspices of the Generic Drug Division. Seife and Rosen outlined a two-step approach to such a transfer. The suggestions from the two FDAers echo a recommendation made by P-A President Jim Cope at the association's 1986 annual meeting. Cope suggested that the agency's high level of productivity in ANDA reviews might be used to breathe new life into the Rx-to-OTC effort ("The Pink Sheet" May 19, 1986, p. 6). In his description of the two-step ANDA switch process, Rosen explained that applicants first have "to come in and get the product approved as . . . an Rx product; then a second step post-approval, you come in with a supplement to your application . . . which basically provides us with clinical data to support the change you want to make." At that point, FDA can "bring that supplement to the appropriate [drug review] office," Rosen continued. "And one of the nice things about that is that you get to work on our time clock, rather than on theirs." Seife agreed: "The advantage of coming to us is that statutory time clock. We honor that 180-day limit . . . so you get your approval and then come in with your supplement . . . think it out with us, and then we'll take the active role in seeing where we can go from there." Rosen cautioned, however, that the approach has not been used, and therefore involves some risk. "This is a new process, we haven't done this yet and we don't know if it's going to work. But we'll give it a try; we'll give it our best shot." Co-panelist and D.C. attorney Robert Pinco (Finley Kumble Wagner) reiterated Rosen's caution. His remarks were in response to a question regarding the effectiveness of the approach for a switch involving a major change, such as a lower dose, or a new indication. Pinco said the ANDA supplement approach "is not a panacea; it's not the final answer. Marvin [Seife] has some limitations when he sends this information down" to the drug review division for a consultation. "If it's really a dramatic change, you ought to do some negotiating early on to see that you're not going to run into a brick wall on the other end," Pinco advised. "All this [approach] does is assure that once you make that decision, once you get some agreement, rather than languishing in their NDA supplement route, you have another mechanism that might work fast." Seife also encouraged sponsors to pursue ANDA approvals for OTCs still covered by patents. "If you have your eye on an OTC product that has a full NDA and a patent that's going to lapse in five years, you can come in and file an ANDA and I'll give you an approval letter saying the effective date is 2002," he said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel